source
- Sellas cancer vaccine cuts death risk by 41% in late-stage AML trialSellas Life Sciences announced results from its Phase 3 REGAL trial evaluating an off‑the‑shelf cancer vaccine in patients with acute myeloid leukemia (AML). The study enrolled 126 individuals who…
- Isomorphic Labs secures $5 billion Series C, doubling its recent $2.1 billion raiseIsomorphic Labs, an AI‑driven drug discovery startup spun out of DeepMind, announced a $5 billion Series C financing, marking its second multibillion‑dollar round within six months. The funding fo…